The human microbiome is a source of therapeutic drug targets

Current Opinion in Chemical Biology

Volumn 17, Issue 3, 2013, Pages 379-384

  Wallace, Bret D ^a,c   Redinbo, Matthew R ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ENZYME; BETA GLUCURONIDASE; BETA GLUCURONIDASE INHIBITOR; DICLOFENAC; FIRTECAN; FIRTECAN GLUCURONIDE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLYCOSIDASE INHIBITOR; INDOMETACIN; IRINOTECAN; NONSTEROID ANTIINFLAMMATORY AGENT; SULFANILAMIDE DERIVATIVE; SULFATE; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BACTERIAL METABOLISM; DEACETYLATION; DIARRHEA; DIGESTIVE SYSTEM INJURY; DRUG ACETYLATION; DRUG CONJUGATION; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; ESCHERICHIA COLI; HUMAN; INTESTINE FLORA; MAMMAL CELL; NONHUMAN; PROTEIN EXPRESSION; REVIEW; STOMACH ULCER; SYMBIONT; SYMBIOSIS;

ANIMALS; DRUG DISCOVERY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEALTH; HUMANS; MICROBIOTA; MOLECULAR TARGETED THERAPY; PHARMACEUTICAL PREPARATIONS;

MAMMALIA;

EID: 84878886096     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2013.04.011     Document Type: Review

References (50)

1. Human Microbiome Project C Structure, function and diversity of the healthy human microbiome. Nature 2012, 486:207-214.
2. Nicholson J.K., Holmes E., Kinross J., Burcelin R., Gibson G., Jia W., Pettersson S. Host-gut microbiota metabolic interactions. Science 2012, 33:1262-1267.
3. Sonnenburg J.L., Fischbach M.A. Community health care: therapeutic opportunities in the human microbiome. Sci Transl Med 2011, 3:ps12.
4. Kau A.L., Ahern P.P., Griffin N.W., Goodman A.L., Gordon J.I. Human nutrition, the gut microbiome and the immune system. Nature 2011, 474:327-336.
5. Gonzalez A., Stombaugh J., Lozupone C., Turnbaugh P.J., Gordon J.I., Knight R. The mind-body-microbial continuum. Dialogues Clin Neurosci 2011, 13:55-62.
6. Plottel C.S., Blaser M.J. Microbiome and malignancy. Cell Host Microbe 2011, 10:324-335.
7. Haiser H.J., Turnbaugh P.J. Is it time for a metagenomic basis of therapeutics?. Science 2012, 336:1253-1255.
8. Wang Z., Klipfell E., Bennett B.J., Koeth R., Levison B.S., Dugar B., Feldstein A.E., Britt E.B., Fu X., Chung Y.M., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472:57-63.
9. Marchesi J.R., Holmes E., Khan F., Kochhar S., Scanlan P., Shanahan F., Wilson I.D., Wang Y. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 2007, 6:546-551.
10. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
11. Wen L., Ley R.E., Volchkov P.Y., Stranges P.B., Avanesyan L., Stonebraker A.C., Hu C., Wong F.S., Szot G.L., Bluestone J.A., et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008, 455:1109-1113.
12. Hooper L.V., Gordon J.I. Commensal host-bacterial relationships in the gut. Science 2001, 292:1115-1118.
13. Hooper L.V., Wong M.H., Thelin A., Hansson L., Falk P.G., Gordon J.I. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001, 291:881-884.
14. Gordon J.I. Honor thy gut symbionts redux. Science 2012, 336:1251-1253.
15. Goodman A.L., McNulty N.P., Zhao Y., Leip D., Mitra R.D., Lozupone C.A., Knight R., Gordon J.I. Identifying genetic determinants needed to establish a human gut symbiont in its habitat. Cell Host Microbe 2009, 6:279-289.
16. Koren O., Goodrich J.K., Cullender T.C., Spor A., Laitinen K., Backhed H.K., Gonzalez A., Werner J.J., Angenent L.T., Knight R., et al. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell 2012, 150:470-480.
17. Crawford P.A., Crowley J.R., Sambandam N., Muegge B.D., Costello E.K., Hamady M., Knight R., Gordon J.I. Regulation of myocardial ketone body metabolism by the gut microbiota during nutrient deprivation. Proc Natl Acad Sci U S A 2009, 106:11276-11281.
18. Simon G.M., Cheng J., Gordon J.I. Quantitative assessment of the impact of the gut microbiota on lysine epsilon-acetylation of host proteins using gnotobiotic mice. Proc Natl Acad Sci U S A 2012, 109:11133-11138.
19. Hehemann J.H., Correc G., Barbeyron T., Helbert W., Czjzek M., Michel G. Transfer of carbohydrate-active enzymes from marine bacteria to Japanese gut microbiota. Nature 2010, 464:908-912.
20. Holmes E., Kinross J., Gibson G.R., Burcelin R., Jia W., Pettersson S., Nicholson J.K. Therapeutic modulation of microbiota-host metabolic interactions. Sci Transl Med 2012, 4:rv136.
21. Shanahan F. The gut microbiota-a clinical perspective on lessons learned. Nat Rev Gastroenterol Hepatol 2012, 9:609-614.
22. Wikoff W.R., Anfora A.T., Liu J., Schultz P.G., Lesley S.A., Peters E.C., Siuzdak G. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A 2009, 106:3698-3703.
23. Clayton T.A., Baker D., Lindon J.C., Everett J.R., Nicholson J.K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A 2009, 106:14728-14733.
24. Maurice C.F., Haiser H.J., Turnbaugh P.J. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 2013, 152:39-50.
25. Fuller A.T. Is p-aminobenzenesulphonamide the active agent of prontosil therapy?. Lancet 1937, 1:194-198.
26. Sousa T., Paterson R., Moore V., Carlsson A., Abrahamsson B., Basit A.W. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 2008, 363:1-25.
27. Okuda H., Ogura K., Kato A., Takubo H., Watabe T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther 1998, 287:791-799.
28. Smith R.V. Metabolism of drugs and other foreign compounds by intestinal microorganisms. World Rev Nutr Diet 1978, 29:60-76.
29. Wallace B.D., Wang H., Lane K.T., Scott J.E., Orans J., Koo J.S., Venkatesh M., Jobin C., Yeh L.A., Mani S., et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010, 330:831-835.
30. Pommier Y. Topoisomerase I. inhibitors: camptothecins and beyond. Nat Rev Cancer 2006, 6:789-802.
31. Champoux J.J. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001, 70:369-413.
32. Staker B.L., Hjerrild K., Feese M.D., Behnke C.A., Burgin A.B., Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A 2002, 99:15387-15392.
33. Chrencik J.E., Burgin A.B., Pommier Y., Stewart L., Redinbo M.R. Structural impact of the leukemia drug 1-beta-d-arabinofuranosylcytosine (Ara-C) on the covalent human topoisomerase I-DNA complex. J Biol Chem 2003, 278:12461-12466.
34. Lesher D.T., Pommier Y., Stewart L., Redinbo M.R. 8-Oxoguanine rearranges the active site of human topoisomerase I. Proc Natl Acad Sci U S A 2002, 99:12102-12107.
35. Kaneda N., Yokokura T. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 1990, 50:1721-1725.
36. Kehrer D.F., Sparreboom A., Verweij J., de Bruijn P., Nierop C.A., van de Schraaf J., Ruijgrok E.J., de Jonge M.J. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001, 7:1136-1141.
37. Blaser M. Antibiotic overuse: stop the killing of beneficial bacteria. Nature 2011, 476:393-394.
38. Levy S.B., Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004, 10:S122-S129.
39. Wu B. Use of physiologically based pharmacokinetic models to evaluate the impact of intestinal glucuronide hydrolysis on the pharmacokinetics of aglycone. J Pharm Sci 2012, 101:1281-1301.
40. LoGuidice A., Wallace B.D., Bendel L., Redinbo M.R., Boelsterli U.A. Pharmacologic targeting of bacterial beta-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. J Pharmacol Exp Ther 2012, 341:447-454.
41. Scarpignato C., Hunt R.H. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am 2010, 39:433-464.
42. Boelsterli U.A., Redinbo M.R., Saitta K. Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies. Toxicol Sci 2012, 131:654-667.
43. Zhu Y., Zhang Q.Y. Role of intestinal cytochrome p450 enzymes in diclofenac-induced toxicity in the small intestine. J Pharmacol Exp Ther 2012, 343:362-370.
44. Sommer M.O., Dantas G., Church G.M. Functional characterization of the antibiotic resistance reservoir in the human microflora. Science 2009, 325:1128-1131.
45. Weigel L.M., Clewell D.B., Gill S.R., Clark N.C., McDougal L.K., Flannagan S.E., Kolonay J.F., Shetty J., Killgore G.E., Tenover F.C. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 2003, 302:1569-1571.
46. F conjugative plasmids. RNA Biol 2013, 10:1-13.
47. Kinross J.M., Darzi A.W., Nicholson J.K. Gut microbiome-host interactions in health and disease. Genome Med 2011, 3:14.
48. Nicaise C., Prozzi D., Viaene E., Moreno C., Gustot T., Quertinmont E., Demetter P., Suain V., Goffin P., Deviere J., et al. Control of acute, chronic, and constitutive hyperammonemia by wild-type and genetically engineered Lactobacillus plantarum in rodents. Hepatology 2008, 48:1184-1192.
49. Jones M.L., Chen H., Ouyang W., Metz T., Prakash S. Microencapsulated genetically engineered lactobacillus plantarum 80 (pCBH1) for bile acid deconjugation and its implication in lowering cholesterol. J Biomed Biotechnol 2004, 2004:61-69.
50. Takiishi T., Korf H., Van Belle T.L., Robert S., Grieco F.A., Caluwaerts S., Galleri L., Spagnuolo I., Steidler L., Van Huynegem K., et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 2012, 122:1717-1725.